title: Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory.
abstract: Identification of poor and rapid metabolizers for the category of drugs metabolized by cytochrome P450 2B6 (CYP2B6) is important for understanding the differences in clinical responses of drugs metabolized by this enzyme. This study reports the prevalence of poor and rapid metabolizers in North Indian population residing in the National Capital Territory. The prevalence of poor and rapid metabolizers was determined in the target population for the category of drugs metabolized by CYP2B6 by measuring plasma bupropion, a drug metabolized by CYP2B6, and its metabolite. Bupropion (75 mg) was administered to 107 volunteers, and the drug (bupropion) and its metabolite (hydroxybupropion) were determined simultaneously by LCMS/MS in the plasma. CYP2B6 activity was measured as hydroxybupropion/bupropion ratio, and volunteers were categorized as rapid or poor metabolizers on the basis of cutoff value of log (hydroxybupropion/bupropion). Significant differences were observed between the mean metabolite/drug ratio of rapid metabolizers (Mean = 0.59) and poor metabolizers (Mean = 0.26) with p<0.0001. Results indicate that 20.56% individuals in the target population were poor metabolizers for the category of drugs metabolized by CYP2B6. Cutoff value defined in this study can be used as a tool for evaluating the status of CYP2B6 using bupropion as a probe drug. The baseline information would be clinically useful before administering the drugs metabolized by this isoform.
authors: Department of Biochemistry, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062 India.
authors: Ekta
authors: E
authors: Varshney
authors: Nilanjan
authors: N
authors: Saha
authors: Monika
authors: M
authors: Tandon
authors: Vikesh
authors: V
authors: Shrivastava
authors: Shakir
authors: S
authors: Ali
keywords: Bupropion; CYP2B6; Cytochrome P450; Drug metabolism; India; LCMS/MS
references: Drug Metab Dispos. 2000 Oct;28(10):1222-30
references: 10997944
references: Clin Pharmacol Ther. 2003 Jul;74(1):32-43
references: 12844133
references: Eur J Clin Pharmacol. 2006 Apr;62(4):267-75
references: 16506047
references: Carcinogenesis. 2001 May;22(5):787-93
references: 11323399
references: Clin Pharmacol Ther. 1998 Apr;63(4):422-7
references: 9585796
references: Pharm Res. 2006 Sep;23(9):1983-90
references: 16951995
references: Drug Metab Dispos. 2003 Apr;31(4):398-403
references: 12642465
references: Drug Metab Pharmacokinet. 2004 Dec;19(6):444-52
references: 15681899
references: Clin Chem. 2007 Jan;53(1):24-33
references: 17082249
references: Eur J Clin Pharmacol. 2002 Sep;58(6):417-21
references: 12242601
references: Pharmacogenomics J. 2003;3(1):53-61
references: 12629583
references: Pharmacogenomics. 2004 Oct;5(7):895-931
references: 15469410
references: Environ Toxicol Pharmacol. 2010 Mar;29(2):126-30
references: 21787593
references: Clin Infect Dis. 2007 Nov 1;45(9):1230-7
references: 17918089
references: Pharmacogenetics. 2003 Oct;13(10):619-26
references: 14515060
references: Pharmacogenet Genomics. 2005 Jan;15(1):1-5
references: 15864119
references: Pharmacogenetics. 2001 Jul;11(5):399-415
references: 11470993
references: Br J Clin Pharmacol. 2003 Sep;56(3):331-3
references: 12919183
references: Pharmacogenet Genomics. 2005 Dec;15(12):861-73
references: 16272958
references: Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):787-91
references: 9923585
references: Drug Metab Rev. 2002 Feb-May;34(1-2):83-448
references: 11996015
references: AIDS. 2004 Dec 3;18(18):2391-400
references: 15622315
references: Mol Pharmacol. 2005 May;67(5):1772-82
references: 15722458
references: Drug Metab Dispos. 2004 Dec;32(12):1341-4
references: 15383491
references: Drug Metab Dispos. 2009 Oct;37(10):1991-3
references: 19581387
references: Drug Metab Dispos. 1999 Dec;27(12):1488-95
references: 10570031
references: Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6
references: 15194512
references: Biochem Biophys Res Commun. 2001 Mar;281(5):1256-60
references: 11243870
references: Clin Infect Dis. 2005 Feb 1;40(3):e22-3
references: 15668854
references: Drug Metab Pharmacokinet. 2004 Apr;19(2):155-8
references: 15499182
references: Int J Mol Med. 2003 Jan;11(1):125-31
references: 12469231
references: Curr Drug Metab. 2008 Sep;9(7):598-610
references: 18781911
references: Clin Infect Dis. 2005 May 1;40(9):1358-61
references: 15825040
references: Clin Pharmacol Ther. 2007 Apr;81(4):557-66
references: 17235330
references: Antimicrob Agents Chemother. 2009 Mar;53(3):863-8
references: 19124658
references: Pharmacogenetics. 2004 Apr;14(4):225-38
references: 15083067
references: AIDS. 2001 Jan 5;15(1):71-5
references: 11192870
references: J Pharmacol Exp Ther. 2003 Jul;306(1):287-300
references: 12676886
references: Drug Metab Dispos. 2011 Jan;39(1):92-7
references: 20876786
references: J Pharmacol Exp Ther. 2003 Dec;307(3):906-22
references: 14551287